Group 1 - The core viewpoint of the article highlights that Hualan Co., Ltd. has seen a significant increase in its stock price, closing at 51.18 yuan with a rise of 5.35%, while its rolling PE ratio reached a new low of 165.92 times over the past 947 days, with a total market value of 8.404 billion yuan [1] - The average PE ratio for the medical device industry is 50.65 times, with a median of 38.17 times, positioning Hualan Co., Ltd. at the 111th rank within the industry [1] - As of the third quarter of 2025, seven institutions hold shares in Hualan Co., Ltd., with a total of 71.1719 million shares valued at 3.026 billion yuan [1] Group 2 - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with main products including film-coated rubber stoppers and conventional rubber stoppers [1] - The company has received recognition as a "AAA-level Quality Credit Enterprise" by the Jiangsu Provincial Market Supervision Administration and as a "Demonstration Workshop for Intelligent Manufacturing" by the Jiangsu Provincial Department of Industry and Information Technology [1] - The latest performance report for the third quarter of 2025 shows that the company achieved an operating income of 441 million yuan, a year-on-year increase of 4.36%, and a net profit of 53.316 million yuan, a year-on-year increase of 2.06%, with a sales gross margin of 38.92% [1]
华兰股份收盘上涨5.35%，滚动市盈率165.92倍，总市值84.04亿元